Cornea verticillata in Fabry disease


Cite item

Full Text

Abstract

Cornea verticillata is the typical sign of ocular involvement in Fabry disease and manifests by the whorl-like, linear opacities in the inferior part of the cornea. Aim. To study the frequency of cornea verticillata in patients with Fabry disease and it’s relation to the severity of the disease and the types of mutation in the GLA gene. Materials and methods. We studied 69 adult (over 18 years) patients with a classic form of Fabry disease that was confirmed by enzymatic and molecular genetic studies. There were 39 males and 30 females. The median age was 39 years [30.0; 50.0]. The severity of Fabry disease was assessed using the Mainz Severity Score Index (MSSI) with a maximum value of 76 points. Depending on the MSSI score, patients were classified into mild (<20), moderate (20-40), and severe (>40) clinical categories. Results and discussion. At least one classic symptom of Fabry disease was present in 88.4% of patients. The majority of patients had the missense mutations of the GLA gene. Cornea verticillata was found in 65.2% of patients and occurred with a similar frequency in males (56.4%) and females (76.7%; p=0.07). Cornea verticillata was the single classic symptom of Fabry disease in only 4.9% of cases, while the rest of the patients presented with angiokeratoma, neuropathic pain and/or hypohidrosis. The frequency of classic symptoms of Fabry disease, as well as renal disease (with the exception of terminal chronic renal failure), brain and heart damage was similar in patients with and without cornea verticillata. Median MSSI scores were also similar in patienths with and without cornea verticillata (20.0 and 18.5 points, respectively; p=0.92). Similar results were obtained in males (26.5 and 30.0 points, p=0.97) and females (16.0 and 16.0 points, p=0.45). The frequency of cornea verticillata did not differ in patients with different types of mutations in the GLA gene. Conclusion. Cornea verticillata occured in 65% of adult patients with Fabry disease, was usually accompanied by the other classic symptoms of the disease, and was not associated with the severity of the disease.

About the authors

S V Moiseev

I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University); M.V. Lomonosov Moscow State University

Email: clinpharm@mtu-net.ru
д.м.н., зав. каф. внутренних, профессиональных болезней и ревматологии Первого МГМУ им. И.М. Сеченова Moscow, Russia

D S Ismailova

Research Institute of Eye Diseases

с.н.с. НИИ Глазных болезней Moscow, Russia

A S Moiseev

M.V. Lomonosov Moscow State University

студент факультета фундаментальной медицины МГУ им. М.В. Ломоносова Moscow, Russia

N M Bulanov

I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

ассистент каф. внутренних, профессиональных болезней и ревматологии Первого МГМУ им. И.М. Сеченова Moscow, Russia

E A Karovaikina

I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

аспирант каф. внутренних, профессиональных болезней и ревматологии Первого МГМУ им. И.М. Сеченова Moscow, Russia

N R Nosova

I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

врач отд-ния ревматологии УКБ №3 Первого МГМУ им. И.М. Сеченова Moscow, Russia

V V Fomin

I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

член-корр. РАН, д.м.н., проф., проректор Первого МГМУ им. И.М. Сеченова Moscow, Russia

References

  1. Моисеев С.В., Новиков П.И., Фомин В.В. Лечение болезни Фабри. Клиническая фармакология и терапия. 2016;25(4):63-70
  2. Мухин Н.А., Моисеев В.С., Моисеев С.В. и др. Диагностика и лечение болезни Фабри. Клиническая фармакология и терапия. 2013;22(2):11-20
  3. Моисеев С.В., Мершина Е.А., Синицын В.Е. и др. Магнитно - резонансная томография в диагностике поражения сердца при болезни Фабри. Клиническая фармакология и терапия. 2017;26(3):13-20
  4. Schiffmann R, Hughes D.A, Linthorst G.E, et al. Screening, diagnosis, and management of patients with Fabry disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 2017;91(2):284-93.
  5. Sodi A, Ioannidis A.S, Mehta A, Davey C, Beck M, Pitz S. Ocular manifestations of Fabry’s disease: data from the Fabry Outcome Survey. Brit J Ophthalmol. 2007;91(2):210-4. doi: 10.1136/bjo.2006.100602
  6. Nielsen C.E, Andreasen F, Bjerregaard P. Amiodarone induced cornea verticillata. Acta Ophthalmol (Copenh). 1983 Jun;61(3):474-80.
  7. Van der Tol L, Sminia M.L, Hollak C.E, Biegstraaten M. Cornea verticillata supports a diagnosis of Fabry disease in non - classical phenotypes: results from the Dutch cohort and a systematic review. Br J Ophthalmol. 2016 Jan;100(1):3-8. doi: 10.1136/bjophthalmol-2014-306433
  8. Pitz S, Kalkum G, Arash L, Karabul N, Sodi A, Larroque S, et al. Ocular Signs Correlate Well with Disease Severity and Genotype in Fabry Disease. PLoS ONE. 2015;10(3):e0120814. doi: 10.1371/ journal.pone.0120814
  9. Whybra C, Kampmann C, Krummenauer F, et al. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet. 2004;65:299-307.
  10. Hughes D.A, Ramaswami U, Barba Romero M.A, Deegan P. Age adjusting severity scores for Anderson-Fabry disease. Mol Genet Metab. 2010;101:219-27.
  11. Моисеев С.В., Намазова-Баранова Л.С., Савостьянов К.В., Моисеев А.С., Фомин В.В. Распространенность и клинические проявления болезни Фабри у диализных пациентов. Клиническая фармакология и терапия. 2017;26(2):27-33

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies